U.S. markets open in 6 hours 45 minutes

X4 Pharmaceuticals, Inc. (XFOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.90+0.33 (+3.45%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close9.57
Open10.10
Bid0.00 x 800
Ask0.00 x 1000
Day's Range9.61 - 10.00
52 Week Range5.38 - 11.11
Volume97,770
Avg. Volume99,313
Market Cap161.237M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.85
Earnings DateMar 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on March 4, 2021
    GlobeNewswire

    X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on March 4, 2021

    BOSTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2020, and provide an update on recent business highlights, on March 4, 2021. The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 1053189. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website. About X4 PharmaceuticalsX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. For more information, please visit www.x4pharma.com. Investors and Media: Daniel FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576 Mónica Rouco MolinaSenior Account ExecutiveLifeSci Communicationsmroucomolina@lifescicomms.com

  • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire

    X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Feb. 02, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on January 29, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 7,450 shares of X4’s common stock and were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and an exercise price of $7.81 per share, which is equal to the closing price of X4’s common stock on January 29, 2021. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant. About X4 Pharmaceuticals, Inc. X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. For more information, please visit www.x4pharma.com. Investors and Media:Daniel Ferry Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576 Mónica Rouco MolinaSenior Account ExecutiveLifeSci Communicationsmroucomolina@lifescicomms.com

  • GlobeNewswire

    X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference

    BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the B. Riley Oncology Institutional Investor Conference on Wednesday, January 20, 2021, at 11:00 am Eastern Time, and conduct one-on-one investor meetings around the event. Details are as follows:Conference: Virtual B. Riley Oncology Institutional Investor ConferenceDate: Wednesday, January 20, 2021Time: 11:00 AM ET B. Riley is limiting the live audience to attendees who register in advance. An archived webcast of the event will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com, following the live fireside chat. The event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days. About X4 PharmaceuticalsX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. For more information, please visit www.x4pharma.com. Investors and Media: Daniel FerryManaging Director LifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576 Mónica Rouco MolinaSenior Account Executive LifeSci Communicationsmroucomolina@lifescicomms.com